<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000368374" LegacyPDQID="" ReplacementFor="CDR0000062721"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq">Chronic Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000039347">chronic myeloproliferative neoplasms</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Chronic Myeloproliferative Neoplasms Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Myeloproliferative Neoplasms Treatment</AltTitle><AltTitle TitleType="Short">Chronic Myeloproliferative Neoplasms Treatment</AltTitle><SummarySection id="_1"><Title>General Information About Chronic Myeloproliferative Neoplasms</Title><SummarySection id="_2"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_3">Myeloproliferative neoplasms are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets. </KeyPoint><Para id="_127">Normally, the <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef> makes <GlossaryTermRef href="CDR0000765906">blood stem cells</GlossaryTermRef> (immature <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef>) that become mature <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> cells over time. </Para><MediaLink ref="CDR0000755927" type="image/jpeg" alt="Anatomy of the bone; drawing shows spongy bone, red marrow, and yellow marrow. A cross section of the bone shows compact bone and blood vessels in the bone marrow. Also shown are red blood cells, white blood cells, platelets, and a blood stem cell." language="en" thumb="Yes" id="_345" size="three-quarters"><Caption language="en">Anatomy of the bone. The bone is made up of compact bone, spongy bone, and bone marrow. Compact bone makes up the outer layer of the bone. Spongy bone is found mostly at the ends of bones and contains red marrow. Bone marrow is found in the center of most bones and has many blood vessels. There are two types of bone marrow: red and yellow. Red marrow contains blood stem cells that can become red blood cells, white blood cells, or platelets. Yellow marrow is made mostly of fat.</Caption></MediaLink><Para id="_344">A blood stem cell may become a <GlossaryTermRef href="CDR0000046279">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000046598">stem cell</GlossaryTermRef> or a <GlossaryTermRef href="CDR0000046298">lymphoid</GlossaryTermRef> stem cell. A lymphoid stem cell becomes a <GlossaryTermRef href="CDR0000045993">white blood cell</GlossaryTermRef>. A myeloid stem cell becomes one of three types of mature blood cells:</Para><ItemizedList id="_128" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046124">Red blood cells</GlossaryTermRef> that carry <GlossaryTermRef href="CDR0000538149">oxygen</GlossaryTermRef> and other substances to all
			 <GlossaryTermRef href="CDR0000046683">tissues</GlossaryTermRef> of the body.</ListItem> 
		  <ListItem>White blood cells that fight <GlossaryTermRef href="CDR0000045364">infection</GlossaryTermRef> and disease.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000045840">Platelets</GlossaryTermRef> that form <GlossaryTermRef href="CDR0000476017">blood clots</GlossaryTermRef> to stop bleeding.</ListItem></ItemizedList><MediaLink ref="CDR0000526219" type="image/jpeg" alt="Blood cell development; drawing shows the steps a blood stem cell goes through to become a red blood cell, platelet, or white blood cell.  Drawing shows a myeloid stem cell becoming a red blood cell, platelet, or myeloblast, which then becomes a white blood cell. Drawing also shows a lymphoid stem cell becoming a lymphoblast and then one of several different types of white blood cells." language="en" thumb="Yes" id="_302" size="three-quarters"><Caption language="en">Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell.</Caption></MediaLink><Para id="_139"> In <GlossaryTermRef href="CDR0000045210">myeloproliferative neoplasms</GlossaryTermRef>,  too many blood stem cells become one or more types of  blood cells. The neoplasms usually get worse slowly as the number of extra blood cells increases.</Para></SummarySection><SummarySection id="_24"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_25">There are 6 types of chronic myeloproliferative neoplasms.</KeyPoint><Para id="_140">The type of  myeloproliferative neoplasm is based on whether too many red blood cells, white blood cells, or platelets are being made.  Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others are. <GlossaryTermRef href="CDR0000752241">Chronic myeloproliferative neoplasms</GlossaryTermRef> include the following 6 types:</Para><ItemizedList id="_138" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044901">Chronic myelogenous leukemia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000426418">Polycythemia vera</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000306488">Primary myelofibrosis</GlossaryTermRef> (also called chronic idiopathic myelofibrosis). </ListItem><ListItem><GlossaryTermRef href="CDR0000256562">Essential thrombocythemia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000426409">Chronic neutrophilic leukemia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000426408">Chronic eosinophilic leukemia</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_141">These types are described below.  Chronic myeloproliferative neoplasms sometimes become <GlossaryTermRef href="CDR0000045145">acute leukemia</GlossaryTermRef>, in which too many
<GlossaryTermRef href="CDR0000044636">abnormal</GlossaryTermRef> white blood cells are made.
</Para></SummarySection><SummarySection id="_198"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_213">Tests that examine the blood and bone marrow are used to detect (find) and diagnose chronic myeloproliferative neoplasms.</KeyPoint><Para id="_161">The following tests and procedures may be used:</Para><ItemizedList id="_162" Style="bullet" Compact="No"><ListItem><Strong><GlossaryTermRef href="CDR0000270871">Physical exam</GlossaryTermRef> and <GlossaryTermRef href="CDR0000689078">history</GlossaryTermRef></Strong>:  An exam of the body to check general <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient’s health habits and past illnesses and treatments will also be taken.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000729979">Complete blood count (CBC) with differential</GlossaryTermRef></Strong>: A procedure in which a sample of blood is drawn and checked for the following:  
   <ItemizedList id="_166" Style="dash"><ListItem>The number of red blood cells and platelets. 
   </ListItem><ListItem>The number and type of white blood cells.</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108">hemoglobin</GlossaryTermRef> (the <GlossaryTermRef href="CDR0000046092">protein</GlossaryTermRef> that carries oxygen) in the red blood cells. 
   </ListItem><ListItem>The portion of the blood sample made up of red blood cells. 
</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells. " language="en" thumb="Yes" id="_293" size="three-quarters"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000390307">Peripheral blood smear</GlossaryTermRef></Strong>: A procedure in which a sample of blood is checked for the following: <ItemizedList id="_332" Style="dash"><ListItem>Whether there are  red blood cells shaped like teardrops.</ListItem><ListItem>The number and kinds of white blood cells.</ListItem><ListItem>The number of platelets.</ListItem><ListItem>Whether there are <GlossaryTermRef href="CDR0000046503">blast</GlossaryTermRef> cells. </ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000304685">Blood chemistry studies</GlossaryTermRef></Strong>:  A procedure in which a blood sample is checked to measure the amounts of certain substances released into the blood by <GlossaryTermRef href="CDR0000257523">organs</GlossaryTermRef> and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000669655">Bone marrow aspiration and biopsy</GlossaryTermRef></Strong>: The removal of bone marrow, blood, and a small piece of bone by inserting a hollow needle into the hipbone or <GlossaryTermRef href="CDR0000549425">breastbone</GlossaryTermRef>. A <GlossaryTermRef href="CDR0000046244">pathologist</GlossaryTermRef> views the bone marrow, blood, and bone under a <GlossaryTermRef href="CDR0000638184">microscope</GlossaryTermRef> to look for abnormal cells.<MediaLink ref="CDR0000554337" type="image/jpeg" alt="Bone marrow aspiration and biopsy; drawing shows a patient lying face down on a table and a Jamshidi needle (a long, hollow needle) being inserted into the hip bone. Inset shows the Jamshidi needle being inserted through the skin into the bone marrow of the hip bone." language="en" thumb="Yes" id="_342" size="three-quarters"><Caption language="en">Bone marrow aspiration and biopsy. After  a small area of skin is numbed, a Jamshidi needle (a long, hollow needle) is inserted into the patient’s hip bone.  Samples of blood, bone, and bone marrow   are removed for examination under a microscope.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000270737">Cytogenetic analysis</GlossaryTermRef></Strong>: A test in which cells in a sample of blood or bone marrow are viewed under a microscope to look for certain changes in the <GlossaryTermRef href="CDR0000046470">chromosomes</GlossaryTermRef>. Certain diseases or <GlossaryTermRef href="CDR0000407758">disorders</GlossaryTermRef> may be <GlossaryTermRef href="CDR0000046450">diagnosed</GlossaryTermRef> or ruled out based on the chromosomal changes.</ListItem><ListItem><Strong><GeneName>JAK2</GeneName> <GlossaryTermRef href="CDR0000045693">gene</GlossaryTermRef> <GlossaryTermRef href="CDR0000046063">mutation</GlossaryTermRef> test</Strong>: A <GlossaryTermRef href="CDR0000046590">laboratory test</GlossaryTermRef> done on a bone marrow or blood sample to check for a <GeneName>JAK2</GeneName> gene mutation. A <GeneName>JAK2</GeneName> gene mutation is often found in patients with polycythemia vera,  essential thrombocythemia,  or primary myelofibrosis.</ListItem> </ItemizedList></SummarySection></SummarySection><SummarySection id="_222"><Title>Chronic Myelogenous Leukemia</Title><Para id="_224"><GlossaryTermRef href="CDR0000044901">Chronic myelogenous leukemia</GlossaryTermRef> is a disease in which too many <GlossaryTermRef href="CDR0000045993">white blood cells</GlossaryTermRef> are made in the <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef>. See the <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> summary on <SummaryRef href="CDR0000258006" url="/types/leukemia/patient/cml-treatment-pdq">Chronic Myelogenous Leukemia Treatment</SummaryRef> for information on <GlossaryTermRef href="CDR0000046450">diagnosis</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046597">staging</GlossaryTermRef>, and treatment.</Para></SummarySection><SummarySection id="_225"><Title>Polycythemia Vera</Title><SummarySection id="_276"><KeyPoint id="_226">Polycythemia vera is a disease in which too many red blood cells are made in the bone marrow.</KeyPoint><Para id="_227">In <GlossaryTermRef href="CDR0000426418">polycythemia vera</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> becomes thickened with too many <GlossaryTermRef href="CDR0000046124">red blood cells</GlossaryTermRef>. The number of <GlossaryTermRef href="CDR0000045993">white blood cells</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045840">platelets</GlossaryTermRef> may also increase. These extra blood <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef> may collect in the <GlossaryTermRef href="CDR0000046593">spleen</GlossaryTermRef> and cause it to swell.  The increased number of red blood cells, white blood cells, or platelets in the blood can cause bleeding problems and make clots form in <GlossaryTermRef href="CDR0000045020">blood vessels</GlossaryTermRef>. This can increase the risk of <GlossaryTermRef href="CDR0000439425">stroke</GlossaryTermRef> or heart attack.  In patients who are older than 65 years or who have a <GlossaryTermRef href="CDR0000642021">history</GlossaryTermRef> of  <GlossaryTermRef href="CDR0000476017">blood clots</GlossaryTermRef>, the risk of stroke or heart attack  is higher. Patients also have an increased risk of <GlossaryTermRef href="CDR0000046347">acute myeloid leukemia</GlossaryTermRef> or <GlossaryTermRef href="CDR0000306488">primary myelofibrosis</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_277"><KeyPoint id="_228">Symptoms of polycythemia vera include headaches and a feeling of fullness below the ribs on the left side.</KeyPoint><Para id="_229">Polycythemia vera often does not cause early <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107">blood test</GlossaryTermRef>. Signs and symptoms may occur as the number of blood cells increases. Other <GlossaryTermRef href="CDR0000651193">conditions</GlossaryTermRef> may cause the same signs and symptoms. Check with your doctor if you have any of the  following:</Para><ItemizedList id="_230" Style="bullet"><ListItem>A feeling of pressure or fullness below the ribs on the left side.</ListItem><ListItem>Headaches.</ListItem><ListItem>Double vision or seeing dark or blind spots that come and go.</ListItem><ListItem>Itching all over the body, especially after being in warm or hot water.</ListItem><ListItem>Reddened face that looks like a blush or sunburn.</ListItem><ListItem>Weakness.</ListItem><ListItem>Dizziness.</ListItem><ListItem>Weight loss for no known reason.</ListItem></ItemizedList></SummarySection><SummarySection id="_278"><KeyPoint id="_231">Special blood tests are used to diagnose polycythemia vera.</KeyPoint><Para id="_232">In addition to a <GlossaryTermRef href="CDR0000045107">complete blood count</GlossaryTermRef>, <GlossaryTermRef href="CDR0000669655">bone marrow aspiration and biopsy</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000270737">cytogenetic analysis</GlossaryTermRef>, a <GlossaryTermRef href="CDR0000044088">serum</GlossaryTermRef> <GlossaryTermRef href="CDR0000045958">erythropoietin</GlossaryTermRef> test is used to <GlossaryTermRef href="CDR0000046450">diagnose</GlossaryTermRef> polycythemia vera. In this test, a sample of blood is checked for the level of erythropoietin (a <GlossaryTermRef href="CDR0000045713">hormone</GlossaryTermRef> that stimulates new red blood cells to be made). In polycythemia vera, the erythropoietin level would be lower than normal because the body does not need to make more red blood cells. </Para></SummarySection></SummarySection><SummarySection id="_234"><Title>Primary Myelofibrosis</Title><SummarySection id="_279"><KeyPoint id="_235">Primary myelofibrosis is a disease in which abnormal blood cells and fibers build up inside the bone marrow.</KeyPoint><Para id="_236">The <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef> is made of <GlossaryTermRef href="CDR0000046683">tissues</GlossaryTermRef> that make <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef> (<GlossaryTermRef href="CDR0000046124">red blood cells</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045993">white blood cells</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045840">platelets</GlossaryTermRef>) and a web of fibers that support the blood-forming tissues.  In <GlossaryTermRef href="CDR0000306488">primary myelofibrosis</GlossaryTermRef> (also called chronic idiopathic myelofibrosis), large numbers of <GlossaryTermRef href="CDR0000765906">blood stem cells</GlossaryTermRef> become blood cells that do not mature properly (<GlossaryTermRef href="CDR0000046503">blasts</GlossaryTermRef>). The web of fibers inside the bone marrow also becomes very thick (like <GlossaryTermRef href="CDR0000640078">scar tissue</GlossaryTermRef>) and slows the blood-forming tissue’s ability to make blood cells.  This causes the blood-forming tissues to make fewer and fewer blood cells.  In order to make up for the low number of blood cells made in the bone marrow, the <GlossaryTermRef href="CDR0000046312">liver</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046593">spleen</GlossaryTermRef> begin to make the blood cells.</Para></SummarySection><SummarySection id="_280"><KeyPoint id="_237">Symptoms of primary myelofibrosis include pain below the ribs on the left side and feeling very tired.</KeyPoint><Para id="_238">Primary myelofibrosis often does not cause early <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107">blood test</GlossaryTermRef>. Signs and symptoms may be caused by primary myelofibrosis or by other <GlossaryTermRef href="CDR0000651193">conditions</GlossaryTermRef>. Check with your doctor if you have any of the  following:</Para><ItemizedList id="_239" Style="bullet"><ListItem>Feeling pain or fullness below the ribs on the left side.</ListItem><ListItem>Feeling full sooner than normal when eating.</ListItem><ListItem>Feeling very tired.</ListItem><ListItem>Shortness of breath.</ListItem><ListItem>Easy bruising or bleeding.</ListItem><ListItem><GlossaryTermRef href="CDR0000046236">Petechiae</GlossaryTermRef> (flat, red, pinpoint spots under the skin that are caused by bleeding).</ListItem><ListItem><GlossaryTermRef href="CDR0000450108">Fever</GlossaryTermRef>.</ListItem><ListItem>Night sweats.</ListItem><ListItem>Weight loss.</ListItem></ItemizedList></SummarySection><SummarySection id="_282"><KeyPoint id="_242">Certain factors affect prognosis (chance of recovery) and treatment options for  primary myelofibrosis.</KeyPoint><Para id="_243"><GlossaryTermRef href="CDR0000045849">Prognosis</GlossaryTermRef> (chance of <GlossaryTermRef href="CDR0000454708">recovery</GlossaryTermRef>) depends on the following:</Para><ItemizedList id="_244" Style="bullet"><ListItem>The age of the patient.</ListItem><ListItem>The number of <GlossaryTermRef href="CDR0000044636">abnormal</GlossaryTermRef> red blood cells and white blood cells.</ListItem><ListItem>The number of blasts in the blood.</ListItem><ListItem>Whether there are certain changes in the <GlossaryTermRef href="CDR0000046470">chromosomes</GlossaryTermRef>.</ListItem><ListItem>Whether the patient has signs such as fever, night sweats, or weight loss.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_245"><Title>Essential Thrombocythemia</Title><SummarySection id="_283"><KeyPoint id="_246">Essential thrombocythemia is a disease in which too many platelets are made in the bone marrow.</KeyPoint><Para id="_247"><GlossaryTermRef href="CDR0000256562">Essential thrombocythemia</GlossaryTermRef> causes an <GlossaryTermRef href="CDR0000044636">abnormal</GlossaryTermRef> increase in the number of <GlossaryTermRef href="CDR0000045840">platelets</GlossaryTermRef> made in the <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_284"><KeyPoint id="_248">Patients with essential thrombocythemia may have no signs or symptoms.</KeyPoint><Para id="_249">Essential thrombocythemia often does not cause early <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107">blood test</GlossaryTermRef>. Signs and symptoms may be caused by essential thrombocytopenia or by other <GlossaryTermRef href="CDR0000651193">conditions</GlossaryTermRef>.  Check with your doctor if you have any of the  following:</Para><ItemizedList id="_250" Style="bullet"><ListItem>Headache.</ListItem><ListItem>Burning or tingling in the hands or feet.</ListItem><ListItem>Redness and warmth of the hands or feet.</ListItem><ListItem>Vision or hearing problems.</ListItem></ItemizedList><Para id="_251">Platelets are sticky. When there are too many platelets, they may clump together and make it hard for the blood to flow.  Clots may form in <GlossaryTermRef href="CDR0000045020">blood vessels</GlossaryTermRef> and there may also be increased bleeding. These can cause serious health problems such as <GlossaryTermRef href="CDR0000439425">stroke</GlossaryTermRef> or heart attack.</Para></SummarySection><SummarySection id="_285"><KeyPoint id="_252">Certain factors affect prognosis (chance of recovery) and treatment options for essential thrombocythemia.</KeyPoint><Para id="_253"><GlossaryTermRef href="CDR0000045849">Prognosis</GlossaryTermRef> (chance of <GlossaryTermRef href="CDR0000454708">recovery</GlossaryTermRef>) and treatment options depend on the following:</Para><ItemizedList id="_254" Style="bullet"><ListItem>The age of the patient.</ListItem><ListItem>Whether the patient has signs or symptoms or other problems related to essential thrombocythemia.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_255"><Title>Chronic Neutrophilic Leukemia</Title><Para id="_257"><GlossaryTermRef href="CDR0000426409">Chronic neutrophilic leukemia</GlossaryTermRef> is a disease in which too many <GlossaryTermRef href="CDR0000765906">blood stem cells</GlossaryTermRef> become a type of <GlossaryTermRef href="CDR0000045993">white blood cell</GlossaryTermRef> called <GlossaryTermRef href="CDR0000046270">neutrophils</GlossaryTermRef>. Neutrophils are <GlossaryTermRef href="CDR0000045364">infection</GlossaryTermRef>-fighting <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef> that surround and destroy dead cells and <GlossaryTermRef href="CDR0000698772">foreign</GlossaryTermRef> substances (such as <GlossaryTermRef href="CDR0000044123">bacteria</GlossaryTermRef>). The <GlossaryTermRef href="CDR0000046593">spleen</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046312">liver</GlossaryTermRef> may swell because of the extra neutrophils. Chronic neutrophilic leukemia may stay the same or it may <GlossaryTermRef href="CDR0000044078">progress</GlossaryTermRef> quickly to <GlossaryTermRef href="CDR0000045145">acute leukemia</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_258"><Title>Chronic Eosinophilic Leukemia</Title><SummarySection id="_286"><KeyPoint id="_259">Chronic eosinophilic leukemia is a disease in which  too many white blood cells (eosinophils) are made in the bone marrow.</KeyPoint><Para id="_260"><GlossaryTermRef href="CDR0000044844">Eosinophils</GlossaryTermRef> are <GlossaryTermRef href="CDR0000045993">white blood cells</GlossaryTermRef> that react to allergens (substances that cause an <GlossaryTermRef href="CDR0000443292">allergic response</GlossaryTermRef>) and help fight <GlossaryTermRef href="CDR0000045364">infections</GlossaryTermRef> caused by certain <GlossaryTermRef href="CDR0000044310">parasites</GlossaryTermRef>. In <GlossaryTermRef href="CDR0000426408">chronic eosinophilic leukemia</GlossaryTermRef>, there are too many eosinophils in the <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef>, and other <GlossaryTermRef href="CDR0000046683">tissues</GlossaryTermRef>. Chronic eosinophilic leukemia may stay the same for many years or it may <GlossaryTermRef href="CDR0000044078">progress</GlossaryTermRef> quickly to <GlossaryTermRef href="CDR0000045145">acute leukemia</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_287"><KeyPoint id="_261">Signs and symptoms of chronic eosinophilic leukemia include fever and feeling very tired. </KeyPoint><Para id="_262">Chronic eosinophilic leukemia may not cause early <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>. It may be found during a routine <GlossaryTermRef href="CDR0000045107">blood test</GlossaryTermRef>. Signs and symptoms may be caused by chronic eosinophilic leukemia or by other <GlossaryTermRef href="CDR0000651193">conditions</GlossaryTermRef>. Check with your doctor if you have any of the  following:</Para><ItemizedList id="_263" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000450108">Fever</GlossaryTermRef>.</ListItem><ListItem>Feeling very tired.</ListItem><ListItem>Cough.</ListItem><ListItem>Swelling under the skin around the eyes and lips, in the <GlossaryTermRef href="CDR0000439429">throat</GlossaryTermRef>, or on the hands and feet.</ListItem><ListItem>Muscle pain.</ListItem><ListItem>Itching.</ListItem><ListItem><GlossaryTermRef href="CDR0000306496">Diarrhea</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_20"><Title>Stages of Chronic Myeloproliferative Neoplasms</Title><SummarySection id="_307"><KeyPoint id="_308">There is no standard staging system for chronic myeloproliferative neoplasms.</KeyPoint><Para id="_309"><GlossaryTermRef href="CDR0000046597">Staging</GlossaryTermRef> is the process used to find out how far the <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> has
		  spread. There is no standard <GlossaryTermRef href="CDR0000689095">staging system</GlossaryTermRef> for <GlossaryTermRef href="CDR0000752241">chronic myeloproliferative neoplasms</GlossaryTermRef>.  Treatment is  based on the type of myeloproliferative neoplasm the patient has. It
		  is important to know the type in order to plan treatment.</Para></SummarySection></SummarySection><SummarySection id="_28"><Title>Treatment Option Overview</Title><SummarySection id="_29"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_30">There are different types of treatment for patients with chronic myeloproliferative neoplasms.</KeyPoint><Para id="_31">Different types of treatments are available for patients with <GlossaryTermRef href="CDR0000752241">chronic myeloproliferative neoplasms</GlossaryTermRef>. Some treatments are <GlossaryTermRef href="CDR0000044930">standard</GlossaryTermRef> (the currently used treatment), and some are being tested in <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef>. A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211">research study</GlossaryTermRef> meant to help improve current treatments or obtain information on new treatments. When clinical trials show that a new treatment is better than the  standard treatment, the new treatment may become the standard treatment.    Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.</Para></SummarySection><SummarySection id="_33"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_34">Eleven types of standard treatment are used: </KeyPoint><SummarySection id="_264"><KeyPoint id="_265">Watchful waiting</KeyPoint><Para id="_266"><GlossaryTermRef href="CDR0000045942">Watchful waiting</GlossaryTermRef> is closely <GlossaryTermRef href="CDR0000454803">monitoring</GlossaryTermRef> a patient’s <GlossaryTermRef href="CDR0000651193">condition</GlossaryTermRef> without giving any treatment until <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> appear or change.</Para></SummarySection><SummarySection id="_38"><KeyPoint id="_39">
     Phlebotomy
    </KeyPoint><Para id="_40"><GlossaryTermRef href="CDR0000256580">Phlebotomy</GlossaryTermRef> is a procedure in which <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> is taken from a <GlossaryTermRef href="CDR0000476471">vein</GlossaryTermRef>. A sample of blood may be taken  for tests such as a <GlossaryTermRef href="CDR0000044649">CBC</GlossaryTermRef> or <GlossaryTermRef href="CDR0000304685">blood chemistry</GlossaryTermRef>. Sometimes phlebotomy is used as a treatment and blood is taken from the body to remove extra <GlossaryTermRef href="CDR0000046124">red blood cells</GlossaryTermRef>. Phlebotomy is used in this way to treat some chronic myeloproliferative neoplasms. 
</Para></SummarySection><SummarySection id="_218"><KeyPoint id="_219">
     Platelet apheresis
    </KeyPoint><Para id="_220"><GlossaryTermRef href="CDR0000045840">Platelet</GlossaryTermRef> <GlossaryTermRef href="CDR0000044448">apheresis</GlossaryTermRef> is a treatment that uses a special machine to remove platelets from the blood. Blood is taken from the patient and put through a blood <GlossaryTermRef href="CDR0000046476">cell</GlossaryTermRef> separator where the platelets are removed. The rest of the blood is then returned to the patient’s bloodstream.</Para></SummarySection><SummarySection id="_267"><KeyPoint id="_268">Transfusion therapy</KeyPoint><Para id="_269"><GlossaryTermRef href="CDR0000046001">Transfusion</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045991">blood transfusion</GlossaryTermRef>) is a method of giving red blood cells, <GlossaryTermRef href="CDR0000045993">white blood cells</GlossaryTermRef>, or platelets to replace blood cells destroyed by disease or <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> treatment.</Para></SummarySection><SummarySection id="_35"><KeyPoint id="_36">
     Chemotherapy
    </KeyPoint><Para id="_37"><GlossaryTermRef href="CDR0000045214">Chemotherapy</GlossaryTermRef> is a cancer treatment that uses <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef> to stop the growth of cancer cells, either by killing the cells or by stopping them  from dividing.   When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471">vein</GlossaryTermRef> or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626">systemic chemotherapy</GlossaryTermRef>). When chemotherapy is placed directly into the <GlossaryTermRef href="CDR0000046483">cerebrospinal fluid</GlossaryTermRef>, an <GlossaryTermRef href="CDR0000257523">organ</GlossaryTermRef>, or a body <GlossaryTermRef href="CDR0000463703">cavity</GlossaryTermRef> such as the <GlossaryTermRef href="CDR0000045070">abdomen</GlossaryTermRef>, the drugs mainly affect cancer cells in those areas (<GlossaryTermRef href="CDR0000046559">regional chemotherapy</GlossaryTermRef>).  The way the chemotherapy is given depends on the type and <GlossaryTermRef href="CDR0000045885">stage</GlossaryTermRef> of the cancer being treated.</Para><Para id="_316">See <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef> for more information.</Para></SummarySection><SummarySection id="_44"><KeyPoint id="_45">
     Radiation therapy
    </KeyPoint><Para id="_46"><GlossaryTermRef href="CDR0000044971">Radiation therapy</GlossaryTermRef> is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. There are two types of radiation therapy.  <GlossaryTermRef href="CDR0000046686">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward the cancer.  <GlossaryTermRef href="CDR0000046345">Internal radiation therapy</GlossaryTermRef> uses a <GlossaryTermRef href="CDR0000046550">radioactive</GlossaryTermRef> substance sealed in needles, <GlossaryTermRef href="CDR0000257219">seeds</GlossaryTermRef>, wires, or <GlossaryTermRef href="CDR0000045637">catheters</GlossaryTermRef> that are placed directly into or near the cancer.  The way the radiation therapy is given depends on the type and stage of the cancer being treated.</Para><Para id="_221">Radiation therapy to treat myeloproliferative neoplasms is usually directed at the <GlossaryTermRef href="CDR0000046593">spleen</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_270"><KeyPoint id="_271">Other drug therapy</KeyPoint><Para id="_335"><GlossaryTermRef href="CDR0000045492">Prednisone</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045188">danazol</GlossaryTermRef> are drugs that may be used to treat <GlossaryTermRef href="CDR0000045360">anemia</GlossaryTermRef> in patients with <GlossaryTermRef href="CDR0000306488">primary myelofibrosis</GlossaryTermRef>.</Para><Para id="_272"><GlossaryTermRef href="CDR0000302451">Anagrelide</GlossaryTermRef> therapy is used to reduce the risk of <GlossaryTermRef href="CDR0000476017">blood clots</GlossaryTermRef> in patients who have too many platelets in 
their blood. Low-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000045176">aspirin</GlossaryTermRef> may also be used to reduce the risk of blood clots.</Para><Para id="_310"><GlossaryTermRef href="CDR0000045458">Thalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393761">lenalidomide</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000589401">pomalidomide</GlossaryTermRef> are drugs that prevent <GlossaryTermRef href="CDR0000045020">blood vessels</GlossaryTermRef> from growing into areas of <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> cells. </Para><Para id="_317">See  <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef> for more information.</Para></SummarySection><SummarySection id="_50"><KeyPoint id="_51">
     Surgery
    </KeyPoint><Para id="_52"><GlossaryTermRef href="CDR0000046594">Splenectomy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045570">surgery</GlossaryTermRef> to remove the spleen) may be done if the spleen is enlarged. </Para></SummarySection><SummarySection id="_55"><KeyPoint id="_56">Biologic therapy </KeyPoint><Para id="_57"><GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> is a treatment that uses the patient's <GlossaryTermRef href="CDR0000046356">immune system</GlossaryTermRef> to fight cancer or other diseases.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against disease.  This type of  treatment is also called biotherapy or immunotherapy. <GlossaryTermRef href="CDR0000045324">Interferon alfa</GlossaryTermRef> and <GlossaryTermRef href="CDR0000346467">pegylated interferon alpha</GlossaryTermRef> are <GlossaryTermRef href="CDR0000415238">biologic agents</GlossaryTermRef> commonly used to treat some chronic myeloproliferative neoplasms. </Para><Para id="_311"><GlossaryTermRef href="CDR0000045958">Erythropoietic</GlossaryTermRef> <GlossaryTermRef href="CDR0000045705">growth factors</GlossaryTermRef>    are also biologic agents. They are used to stimulate the <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef> to make red blood cells. </Para></SummarySection><SummarySection id="_336"><KeyPoint id="_337">Targeted therapy</KeyPoint><Para id="_338"><GlossaryTermRef href="CDR0000270742">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. <GlossaryTermRef href="CDR0000044833">Tyrosine kinase inhibitors</GlossaryTermRef> are targeted therapy drugs  that block signals needed for tumors   to grow. </Para><Para id="_339"><GlossaryTermRef href="CDR0000718942">Ruxolitinib</GlossaryTermRef>  is a tyrosine kinase inhibitor used to treat certain types of <GlossaryTermRef href="CDR0000045947">myelofibrosis</GlossaryTermRef>.</Para><Para id="_343">See  <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef> for more information.</Para><Para id="_340">Other types of targeted therapies are being studied in clinical trials.</Para></SummarySection><SummarySection id="_273"><KeyPoint id="_274">High-dose chemotherapy with stem cell transplant</KeyPoint><Para id="_275"><GlossaryTermRef href="CDR0000346522">High-dose chemotherapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000046695">stem cell transplant</GlossaryTermRef> is a method of giving high doses of chemotherapy and replacing blood-forming cells destroyed by the cancer treatment. <GlossaryTermRef href="CDR0000046598">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or bone marrow of the patient or a <GlossaryTermRef href="CDR0000643010">donor</GlossaryTermRef> and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an <GlossaryTermRef href="CDR0000045738">infusion</GlossaryTermRef>. These reinfused stem cells grow into (and restore) the body's blood cells. <MediaLink ref="CDR0000765030" type="image/jpeg" alt="Stem cell transplant; (Panel 1): Drawing of stem cells being removed from a patient or donor. Blood is collected from a vein in the arm and flows through a machine that removes the stem cells; the remaining blood is returned to a vein in the other arm. (Panel 2): Drawing of a health care provider giving a patient treatment to kill blood-forming cells. Chemotherapy is given to the patient through a catheter in the chest. (Panel 3): Drawing of stem cells being given to the patient through a catheter in the chest." language="en" thumb="Yes" id="_346" size="full"><Caption language="en">Stem cell transplant. (Step 1): Blood is taken from a vein in the arm of the donor. The patient or another person may be the donor. The blood flows through a machine that removes the stem cells. Then the blood is returned to the donor through a vein in the other arm. (Step 2): The patient receives chemotherapy to kill blood-forming cells. The patient may receive radiation therapy (not shown). (Step 3): The patient receives stem cells through a catheter placed into a blood vessel in the chest.</Caption></MediaLink></Para></SummarySection></SummarySection><SummarySection id="_53"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_54">New types of treatment are being tested in clinical trials.</KeyPoint><Para id="_59"> Information about clinical trials is available from the
		  <ExternalRef xref="http://cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><SummarySection id="_296"><KeyPoint id="_297">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_296_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930">standard treatment</GlossaryTermRef>.</Para><Para id="_296_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_296_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_298"><KeyPoint id="_299">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_298_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from <GlossaryTermRef href="CDR0000046556">recurring</GlossaryTermRef> (coming back) or reduce the <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_298_30">Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from <GlossaryTermRef href="CDR0000044267">NCI's</GlossaryTermRef> listing of clinical trials. </Para></SummarySection><SummarySection id="_300"><KeyPoint id="_301">Follow-up tests may be needed.</KeyPoint><Para id="_300_33">Some of the tests that were done to <GlossaryTermRef href="CDR0000046450">diagnose</GlossaryTermRef> the cancer or to find out the <GlossaryTermRef href="CDR0000045885">stage</GlossaryTermRef> of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_300_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your <GlossaryTermRef href="CDR0000651193">condition</GlossaryTermRef> has changed or if the cancer has <GlossaryTermRef href="CDR0000046556">recurred</GlossaryTermRef> (come back). These tests are sometimes called <GlossaryTermRef href="CDR0000044671">follow-up</GlossaryTermRef> tests or check-ups.</Para></SummarySection></SummarySection><SummarySection id="_288"><Title>Treatment Options for Chronic Myeloproliferative Neoplasms</Title><SummarySection id="_142"><Title>Chronic Myelogenous Leukemia</Title><Para id="_143">See the <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> summary about <SummaryRef href="CDR0000258006" url="/types/leukemia/patient/cml-treatment-pdq">Chronic Myelogenous Leukemia Treatment</SummaryRef> for information.</Para></SummarySection><SummarySection id="_61"><SectMetaData><SpecificDiagnosis ref="CDR0000039350">polycythemia vera</SpecificDiagnosis></SectMetaData><Title>Polycythemia Vera </Title><SummarySection id="_65"><Para id="_67">The purpose of treatment for <GlossaryTermRef href="CDR0000426418">polycythemia vera</GlossaryTermRef> is to reduce the number of extra <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> <GlossaryTermRef href="CDR0000046476">cells</GlossaryTermRef>.  Treatment of polycythemia vera may include the following: </Para><ItemizedList id="_68" Style="bullet">
    <ListItem><GlossaryTermRef href="CDR0000256580">Phlebotomy</GlossaryTermRef>.</ListItem>
    <ListItem><GlossaryTermRef href="CDR0000045214">Chemotherapy</GlossaryTermRef>  with or without  phlebotomy.</ListItem><ListItem><GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> using <GlossaryTermRef href="CDR0000045324">interferon alfa</GlossaryTermRef> or <GlossaryTermRef href="CDR0000346467">pegylated interferon alpha</GlossaryTermRef>..</ListItem>
    <ListItem>Low-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000045176">aspirin</GlossaryTermRef>.</ListItem>
   </ItemizedList></SummarySection><Para id="_TrialSearch_61_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39350&amp;tt=1&amp;format=1&amp;cn=1">polycythemia vera</ExternalRef>. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.  Talk with your doctor about clinical trials that may be right for you.  General information about clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><SummarySection id="_70"><SectMetaData><SpecificDiagnosis ref="CDR0000039357">primary myelofibrosis</SpecificDiagnosis></SectMetaData><Title>Primary Myelofibrosis</Title><SummarySection id="_74"><Para id="_167">Treatment of <GlossaryTermRef href="CDR0000306488">primary myelofibrosis</GlossaryTermRef> in patients without <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> is usually <GlossaryTermRef href="CDR0000045942">watchful waiting</GlossaryTermRef>.</Para><Para id="_333">Patients with primary myelofibrosis may have signs or symptoms of <GlossaryTermRef href="CDR0000045360">anemia</GlossaryTermRef>. Anemia is usually treated with <GlossaryTermRef href="CDR0000046001">transfusion</GlossaryTermRef> of <GlossaryTermRef href="CDR0000046124">red blood cells</GlossaryTermRef> to relieve symptoms and improve <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef>. In addition, anemia may be treated with: </Para><ItemizedList id="_334" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000045958">Erythropoietic</GlossaryTermRef> <GlossaryTermRef href="CDR0000045705">growth factors</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045492">Prednisone</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045188">Danazol</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045458">Thalidomide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393761">lenalidomide</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000589401">pomalidomide</GlossaryTermRef>, with or without prednisone.</ListItem></ItemizedList><Para id="_76"> Treatment of primary myelofibrosis in patients with other signs or symptoms may include the following:</Para><ItemizedList id="_77" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000270742">Targeted therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000718942">ruxolitinib</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045214">Chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000643010">Donor</GlossaryTermRef> <GlossaryTermRef href="CDR0000046695">stem cell transplant</GlossaryTermRef>.</ListItem><ListItem>Thalidomide, lenalidomide, or pomalidomide.</ListItem>
    
    
   <ListItem><GlossaryTermRef href="CDR0000046594">Splenectomy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044971">Radiation therapy</GlossaryTermRef> to the <GlossaryTermRef href="CDR0000046593">spleen</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045762">lymph nodes</GlossaryTermRef>, or other areas outside the <GlossaryTermRef href="CDR0000045622">bone marrow</GlossaryTermRef> where blood cells are forming.</ListItem><ListItem><GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> using <GlossaryTermRef href="CDR0000045324">interferon alfa</GlossaryTermRef> or     erythropoietic growth factors.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961">clinical trial</GlossaryTermRef> of other targeted therapy <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><Para id="_TrialSearch_70_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39357&amp;tt=1&amp;format=1&amp;cn=1">primary myelofibrosis</ExternalRef>. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.  Talk with your doctor about clinical trials that may be right for you.  General information about clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><SummarySection id="_79"><SectMetaData><SpecificDiagnosis ref="CDR0000039361">essential thrombocythemia</SpecificDiagnosis></SectMetaData><Title>Essential Thrombocythemia</Title><SummarySection id="_83"><Para id="_85">Treatment of <GlossaryTermRef href="CDR0000256562">essential thrombocythemia</GlossaryTermRef> in patients younger than 60  years who have no <GlossaryTermRef href="CDR0000750109">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef> and an acceptable  <GlossaryTermRef href="CDR0000045840">platelet</GlossaryTermRef> count is usually <GlossaryTermRef href="CDR0000045942">watchful waiting</GlossaryTermRef>. Treatment of other patients may include the following:</Para><ItemizedList id="_86" Style="bullet">
    <ListItem><GlossaryTermRef href="CDR0000045214">Chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000302451">Anagrelide</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef>.</ListItem><ListItem> 
<GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> using <GlossaryTermRef href="CDR0000045324">interferon alfa</GlossaryTermRef> or <GlossaryTermRef href="CDR0000346467">pegylated interferon alpha</GlossaryTermRef>.</ListItem><ListItem>Platelet <GlossaryTermRef href="CDR0000044448">apheresis</GlossaryTermRef>.</ListItem>
    
    <ListItem>A <GlossaryTermRef href="CDR0000045961">clinical trial</GlossaryTermRef> of a new treatment.</ListItem>
   </ItemizedList></SummarySection><Para id="_TrialSearch_79_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=39361&amp;tt=1&amp;format=1&amp;cn=1">essential thrombocythemia</ExternalRef>. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.  Talk with your doctor about clinical trials that may be right for you.  General information about clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><SummarySection id="_88"><SectMetaData><SpecificDiagnosis ref="CDR0000276485">chronic neutrophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Chronic Neutrophilic Leukemia </Title><SummarySection id="_92"><Para id="_94">Treatment of <GlossaryTermRef href="CDR0000426409">chronic neutrophilic leukemia</GlossaryTermRef> may include the following:</Para><ItemizedList id="_95" Style="bullet">
    <ListItem><GlossaryTermRef href="CDR0000643010">Donor</GlossaryTermRef> <GlossaryTermRef href="CDR0000045263">bone marrow transplant</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045214">Chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> using <GlossaryTermRef href="CDR0000045324">interferon alfa</GlossaryTermRef>. </ListItem>
    
    <ListItem>A <GlossaryTermRef href="CDR0000045961">clinical trial</GlossaryTermRef> of a new treatment.</ListItem>
   </ItemizedList></SummarySection><Para id="_TrialSearch_88_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=276485&amp;tt=1&amp;format=1&amp;cn=1">chronic neutrophilic leukemia</ExternalRef>. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.  Talk with your doctor about clinical trials that may be right for you.  General information about clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><SummarySection id="_97"><SectMetaData><SpecificDiagnosis ref="CDR0000276487">chronic eosinophilic leukemia</SpecificDiagnosis></SectMetaData><Title>Chronic Eosinophilic Leukemia</Title><SummarySection id="_101"><Para id="_103">Treatment of <GlossaryTermRef href="CDR0000426408">chronic eosinophilic leukemia</GlossaryTermRef> may include the following:</Para><ItemizedList id="_104" Style="bullet">
    <ListItem><GlossaryTermRef href="CDR0000045263">Bone marrow transplant</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045617">Biologic therapy</GlossaryTermRef> using <GlossaryTermRef href="CDR0000045324">interferon alfa</GlossaryTermRef>.</ListItem>
    
    <ListItem>A <GlossaryTermRef href="CDR0000045961">clinical trial</GlossaryTermRef> of a new treatment.</ListItem>
   </ItemizedList></SummarySection><Para id="_TrialSearch_97_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=276487&amp;tt=1&amp;format=1&amp;cn=1">chronic eosinophilic leukemia</ExternalRef>. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug.  Talk with your doctor about clinical trials that may be right for you.  General information about clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><SummarySection id="_290"><Title>To Learn More About Chronic Myeloproliferative Neoplasms</Title><Para id="_291">For more information from the <GlossaryTermRef href="CDR0000044266">National Cancer Institute</GlossaryTermRef> about  chronic myeloproliferative neoplasms, see the following: </Para><ItemizedList id="_319" Style="bullet"><ListItem><ExternalRef xref="http://www.cancer.gov/types/myeloproliferative">Myeloproliferative Neoplasms Home Page</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet">Biological Therapies for Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet">Blood-Forming Stem Cell Transplants</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet">Targeted Cancer Therapies</ExternalRef></ListItem></ItemizedList><Para id="_290_40">For general <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> information and other resources from the National Cancer Institute, see the following:</Para><ItemizedList id="_290_41" Style="bullet"><ListItem><ExternalRef xref="http://www.cancer.gov/cancertopics/factsheet/Detection/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/cancertopics/coping">Coping with Cancer: Supportive and Palliative Care</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/cancertopics/cancerlibrary/questions">Questions to Ask Your Doctor About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.cancer.gov/cancertopics/cancerlibrary">Cancer Library</ExternalRef>
</ListItem><ListItem><ExternalRef xref="http://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors and Caregivers</ExternalRef>
</ListItem></ItemizedList></SummarySection><SummarySection id="_106"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (06/26/2015)</Title><Para id="_107">The <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_306">Editorial changes were made to this summary.</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="http://www.cancer.gov/espanol/recursos/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of chronic myeloproliferative neoplasms.  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials are listed in PDQ and can be found online at <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI's Web site</ExternalRef>. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">National Cancer Institute: PDQ® Chronic Myeloproliferative Neoplasms Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq">http://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 2,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><PatientVersionOf ref="CDR0000062927"/><DateFirstPublished>2005-01-24</DateFirstPublished><DateLastModified>2015-06-26</DateLastModified></Summary>
